Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial Oct 6, 2022 07:55AM
Nova Mentis Begins Enrollment in North American Autism Study Mar 23, 2022 08:30AM
Nova Mentis Announces Closing of Non-Brokered Financing Mar 15, 2022 08:30AM
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism Feb 16, 2022 08:00AM
Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program Dec 16, 2021 08:30AM


Nov 9, 2021 08:30AM Nova Mentis Files Genetic Neuroinflammatory Disease Patent
Nov 2, 2021 08:30AM U.S. FDA Approves Nova Mentis Orphan Drug Application
Oct 26, 2021 08:00AM Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
Oct 19, 2021 08:00AM Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System